Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses experimenting with Sandalore for hair loss and concerns about its authenticity compared to sandalwood oil. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.

The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.

Creating a propylene glycol-free Minoxidil and Tretinoin solution to reduce skin irritation and enhance effectiveness. An emulsifier like lecithin can help mix Tretinoin properly, and Minoxidil foam is an alternative without propylene glycol.

A user offers an extra bottle of Koshine 0.5% solution for hair loss. The discussion involves interest in trying Pyrilutamide for hair treatment.

The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

Aminexil, nanoxidil, stemoxydine, and kopexil are discussed as alternatives to minoxidil for hair growth, with concerns about dependence. Minoxidil is noted for its effectiveness in transitioning hair growth phases, but dependence is mainly linked to androgenic alopecia.

Alcohol-free minoxidil options in Europe, particularly from a German pharmacy, are recommended for those with seborrheic dermatitis. Users suggest alternatives like Alopexy and Doppelherz foam, and emphasize avoiding propylene glycol and alcohol to reduce irritation.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

The conversation discusses a topical hair loss treatment containing 0.1% dutasteride, 6% minoxidil, tretinoin, and ketoconazole. The user is asking for opinions on the effectiveness of this solution.

Azelaic acid is discussed for its anti-inflammatory and anti-fungal properties, which can improve scalp health and potentially boost hair growth. It is suggested for topical use, especially alongside minoxidil.

The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

The user experienced hair regrowth with finasteride and minoxidil but faced libido issues, leading them to try alternatives like novamaine and a low-dose finasteride/minoxidil solution, which still caused side effects. They are considering reducing the solution's volume, stopping finasteride, or using minoxidil alone, while others suggest alternatives like dutasteride or clascoterone.

The conversation is about creating a DIY hair loss treatment solution using pyrilutamide powder, stored in an old minoxidil bottle. The user is seeking advice on how to best replicate Kintor's trials and the ideal storage conditions for the solution.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

The conversation is about whether Saw Palmetto, which has similar but less potent effects to Finasteride, could cause the same side effects due to lowering DHT levels. The user is considering oral Saw Palmetto as an alternative to Finasteride for hair loss treatment.

People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.

The user is currently using Minoxidil with melatonin, rosemary, peppermint, azelaic acid, and RU58841 for hair loss and plans to add fluridil and Pyrilutamide. They seek advice on the best Pyrilutamide source, noting Actifolic worked briefly.

The user has been on finasteride for 16 months and is considering natural remedies like peppermint oil, rosemary oil, saw palmetto, green tea extract, l-lysine, and oral castor oil to enhance hair growth in addition to finasteride. They are interested in the potential benefits of combining these natural treatments with finasteride to improve hair loss outcomes.

The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

User quit minoxidil and finasteride, starting stemoxydine, dermastamp, and dermapen for hair loss. Seeks advice on alternatives, avoiding androgen disruptors and vasodilators/vasoconstrictors.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.